Novocure planning submission for TTFields in mesothelioma

Novocure Ltd. (NASDAQ:NVCR) reported final data from the Phase II STELLAR trial to treat previously untreated unresectable malignant pleural mesothelioma showing that its Tumor Treating

Read the full 256 word article

User Sign In